Crinetics Pharmaceuticals Inc
$ 83.86
0.01%
28 Jul - close price
- Market Cap 8,874,703,000 USD
- Current Price $ 83.86
- High / Low $ 83.98 / 83.84
- Stock P/E N/A
- Book Value 12.16
- EPS -5.14
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.39 %
- 52 Week High 84.00
- 52 Week Low 25.83
About
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California.
Analyst Target Price
$82.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -1.23 | -1.29 | -1.38 | -1.23 | -1.04 | -0.88 | -0.96 | -0.94 | -0.93 | -0.9 | -1.01 | -0.94 |
| Estimated EPS | -1.2 | -1.37 | -1.25 | -1.13 | -0.95 | -0.8919 | -0.91 | -0.86 | -0.81 | -0.86 | -0.88 | -0.85 |
| Surprise | -0.03 | 0.08 | -0.13 | -0.1 | -0.09 | 0.0119 | -0.05 | -0.08 | -0.12 | -0.04 | -0.13 | -0.09 |
| Surprise Percentage | -2.5% | 5.8394% | -10.4% | -8.8496% | -9.4737% | 1.3342% | -5.4945% | -9.3023% | -14.8148% | -4.6512% | -14.7727% | -10.5882% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.23 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRNX
2026-07-27 07:39:19
This article provides details on Crinetics Pharmaceuticals Inc. (CRNX) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock pricing and market capitalization information.
2026-07-27 02:12:35
This article provides the quarterly and annual income statements for Crinetics Pharmaceuticals Inc (CRNX), detailing financial performance from FY2017Q1 to FY2026Q1. It includes metrics such as total revenue, operating expenses, R&D expenses, operating profit, net non-operating interest income/expenses, income before and after tax, and basic and diluted earnings per share. The piece also features a "FAQs" section explaining how to read the income statement and highlighting key financial figures for CRNX.
2026-07-25 21:42:05
This article details the shareholder structure of Crinetics Pharmaceuticals Inc (CRNX), listing its major shareholders and their proportions. It also presents institutional holding trends over recent quarters, and identifies related ETFs that include CRNX. Top shareholders include Fidelity Management & Research Company LLC and Wellington Management Company, LLP.
2026-07-24 14:40:37
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) generated $7.70 million USD in revenue last year, primarily from its Novel Therapeutics segment. The United States was the company's largest contributing region, accounting for the entire $7.70 million USD. This represents a significant increase from the previous year's revenue of $1.04 million USD.
2026-07-24 13:11:11
This article provides an earnings forecast for Crinetics Pharmaceuticals Inc (CRNX), detailing its current earnings forecast score of 8.50 and ranking within the Biotechnology & Medical Research industry. It highlights analyst ratings, price targets, expected revenue, and past EPS performance for the company. The consensus among analysts is a "Hold" rating for CRNX.
2026-07-23 19:40:24
Crinetics Pharmaceuticals Inc. (CRNX) has a current stock price of $83.73, with a market capitalization of $8.86 billion. The company, which specializes in therapeutics for rare endocrine diseases, exhibits strong fundamentals and high growth potential, despite being considered fairly valued by analysts. Institutional ownership is very high, and the stock is performing strongly, with multiple analysts rating it as "Hold" and anticipating an upward trend in the medium term.
